{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-24-000031","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.250232+00:00","generated_at":"2026-06-03T23:09:33.231448+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Biohaven presents BHV-1300 Ph1 SAD data: safe, dose-dependent IgG lowering in 16 subjects","bullets":["16 subjects completed two dosing cohorts; no SAEs, only mild AEs unrelated to drug.","Preliminary dose- and time-dependent IgG lowering observed; IgG1/2/4 reduction greater than IgG3.","BHV-1300 designed to spare IgG3; data consistent with preclinical nonhuman primate models.","Further program update planned at Company's R&D Day on May 29, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-24-000031","json":"https://secwatch.observer/filing/0001935979-24-000031.json","markdown":"https://secwatch.observer/filing/0001935979-24-000031.md","text":"https://secwatch.observer/filing/0001935979-24-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597924000031/0001935979-24-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597924000031/bhvn-20240415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T23:09:33.231448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}